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ABSTRACT: Macrolactonization of natural product analogs
presents a significant challenge to both biosynthetic assembly
and synthetic chemistry. In the preceding paper, we identified
a thioesterase (TE) domain catalytic bottleneck processing
unnatural substrates in the pikromycin (Pik) system,
preventing the formation of epimerized macrolactones. Here,
we perform molecular dynamics simulations showing the
epimerized hexaketide was accommodated within the Pik TE
active site; however, intrinsic conformational preferences of the substrate resulted in predominately unproductive conformations,
in agreement with the observed hydrolysis. Accordingly, we engineered the stereoselective Pik TE to yield a variant (TES148C)
with improved reaction kinetics and gain-of-function processing of an unnatural, epimerized hexaketide. Quantum mechanical
comparison of model TES148C and TEWT reaction coordinate diagrams revealed a change in mechanism from a stepwise
addition−elimination (TEWT) to a lower energy concerted acyl substitution (TES148C), accounting for the gain-of-function and
improved reaction kinetics. Finally, we introduced the S148C mutation into a polyketide synthase module (PikAIII-TE) to
impart increased substrate flexibility, enabling the production of diastereomeric macrolactones.
■ INTRODUCTION
Macrocycles are a common motif among natural product and
natural product derived therapeutics, with >100 marketed drugs
possessing a macrocyclic core.1 The conformational preorgani-
zation of these large rings enables precise display of
functionality to engage challenging targets such as protein−
protein interactions, and, in the case of macrolides, ribosomal
machinery.2−4
The macrolactone core of macrolide5 natural products is
formed through two steps: first, the linear intermediate is
transferred from the upstream acyl carrier protein (ACP) to a
catalytic serine of the TE via a transesterification to form an
acyl-enzyme complex. Next, the acyl intermediate is offloaded
via intermolecular water hydrolysis or intramolecular nucleo-
philic attack to release the product as a linear acid or
macrolactone, respectively6 (Figure 1).
Biochemical and structural studies of the Pik TE and related
DEBS TE (erythromycin pathway) have provided initial
insights into the mechanism of ring formation over
hydrolysis.7,8 While it is generally accepted that modular type
I TEs have high substrate flexibility for the initial acylation step,
the second, macrolactone forming release step is far more
stringent.6 Since the formation of the macrocyclic core is
essential for downstream tailoring and biological activity of a
natural product, aberrant hydrolysis limits access to new
macrocyclic analogs.
In an preceding paper,9 we employed a series of synthetic Pik
pentaketides to evaluate the substrate tolerance of PikAIII-TE.
Characterization of the in vitro reaction products indicated a
catalytic bottleneck localized to the Pik TE domain, preventing
macrolactonization to form C-10 and C-11 epimers of 10-dml
(1). Furthermore, this bottleneck was confirmed directly by
incubation of 5 with Pik TE resulting exclusively in hydrolysis9
(Figure 2). Given the importance of the TE domain in
production of macrolactone analogs, we sought to engineer the
excised Pik TE domain to expand its substrate scope and,
potentially, improve reaction rates. In this study, we report the
identification of a single active site mutation (S148C) in Pik TE
that generates a more effective macrolactonization catalyst by
increasing both the substrate flexibility and efficiency of the
enzyme. Subsequent introduction of the engineered TE into
PikAIII-TE results in a polyketide synthase with increased
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substrate flexibility capable of producing epimeric macro-
lactones.
■ RESULTS
Molecular Dynamics (MD) Simulations of Pik TE
Macrolactonization. Intrigued by the stark catalytic diver-
gence from macrolactonization to hydrolysis in Pik TE
reactions containing hexaketide 5 bearing the epimerized C-
11 hydroxyl group (Figure 2), we envisioned that comparing
MD simulations of Pik TEWT acylated with hexaketides 4 and 5
(denoted Pik TE-4 and Pik TE-5, respectively, Figure 3) could
provide structural insight into these experimental findings.
Accordingly, we performed MD simulations of each catalytic
system modeled as acyl-enzyme intermediates bound to the C-
3 methyl-protected hexaketides (Figure 3), using the
conformation of the derivatized products10 as the starting
arrangement for the individual substrates. MD simulations (see
Computational Details in the Supporting Information) were
initiated with the hexaketide C-11 alcohol constrained in a
reactive conformation by imposing a maximum distance
restraint of 2.3 Å between the hexaketide nucleophilic hydroxyl
hydrogen and the Nε nitrogen of His268. After 50 ns, the
distance restraint was removed and the simulations were
allowed to continue for 500 ns.
Simulations of Pik TE-4 revealed that while the initial
catalytic restraint was in place, the native hexaketide readily
adopts two main conformations favorable toward macro-
lactonization (denoted as I and II, Figure 4a). At the initial
stages of the simulation, conformation I predominates,
accompanied by a high level of shape complementarity with
the TE active site. The main interactions constituting
conformation I are hydrophobic contacts between the
hexaketide and the side chains of residues lining the active
site. Additionally, a hydrogen bond between the hexaketide C-7
carbonyl and the side chain of Thr77 facilitates stabilization of
the cyclic, reactive conformation (Figure S13). After ∼30 ns the
hexaketide evolves to conformation II through a substrate tail
rotation that places the C-11 alcohol 0.2 and 0.7 Å closer to
His268 and the C-1 carbonyl, respectively. This orientation
resembles the macrolactonization transition state (vide inf ra)
even closer than conformation I and is likely catalytically
productive.
Following formation of conformation II, the hexaketide
displays a large amount of conformational freedom within the
TE active site. In the most prevalent conformation (III, Figure
4a) hydrophobic packing is largely reduced and nonproductive
hydrogen bonds between the C-11 alcohol and Tyr25/Leu193
are formed (Figure S13). Loss of the key hydrophobic
Figure 1. Macrolactonization or hydrolysis of an ACP-tethered polyketide intermediate.
Figure 2. Pik TE displays a high level of substrate stereoselectivity. (a)
Pik hexaketides used in this study to probe Pik TE substrate flexibility.
3 is generated in situ by photolysis of the 2-nitrobenzyloxymethyl
ether (NBOM) protected native hexaketide.10 (b) Incubation of C-11-
epimerized Pik hexaketide 5 results exclusively in hydrolysis.9
Figure 3. Acyl-enzyme starting structures for the MD simulations of 4
(Pik TE-4) and C-11-epimerized 5 (Pik TE-5).
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interactions is detrimental to macrolactonization as it increases
the conformational space accessible to the hexaketide, which
adopts a more linear, unreactive conformation. Although
conformation III accounts for the majority of the Pik TE-4
simulation, conformation II developed again later in the
trajectory (406−443 ns, Figure 4c), suggesting that productive
conformations for macrocyclization are frequently sampled
despite the high substrate flexibility.
The simulations of Pik TE-5 involving the C-11-epimerized
hexaketide revealed a significantly different scenario. While the
initial distance restraint was in place, the hexaketide adopted a
cyclic conformation stabilized by hydrophobic packing with the
TE active site (I′, Figure 4b). However, in contrast with the
native hexaketide, the C-11 alcohol of the epimerized
hexaketide is prone to intramolecular hydrogen bonding with
the C-1 carbonyl oxygen. Despite maintaining the substrate in a
cyclic conformation with the nucleophilic hydroxyl in close
proximity to the C-1 carbonyl, the resulting geometry impedes
macrolactonization. Furthermore, His268 remains 4.0 Å away
and positioned at an angle suboptimal for deprotonation,
Figure 4. Comparison of the reactive conformations for each acyl-enzyme intermediate obtained from clustering analysis of MD simulations with Pik
TEWT: (a) Pik TE-4 and (b) Pik TE-5. Pik TE-4 conformations I and II contain a hexaketide orientation most conducive to macrolactonization with
the C-11 OH in close proximity to both His268 and the C-1 carbonyl. The corresponding conformation (cluster I′) in the Pik TE-5 simulation likely
represents a larger barrier to macrolactonization as the distance between the C-11 OH and His268 has increased and the resulting geometry hinders
deprotonation. The Pik TE-5 hexaketide continues to evolve toward a linear conformation until the final cluster III′ is reached which places the C-11
OH distal to both His268 and the C-1 carbonyl and in an orientation susceptible to hydrolysis. The catalytic triad His268 and Asp176 residues are
colored yellow. For each conformation the distance in angstroms from the nucleophilic hydroxyl oxygen to the Nε nitrogen of His268 and the ester
C-1 carbonyl is displayed above the dashed lines. Clusters containing catalytically productive conformations contain red dashed lines. (c) The
distance of the nucleophilic hydroxyl oxygen and the ester C-1 carbonyl plotted for each frame of the MD simulation with each data point colored
according to the corresponding clustered conformation. The vertical dashed line at 50 ns indicates when the distance constraints were released.
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making this conformation catalytically unproductive. After ∼80
ns, unrestricted Pik TE-5 transitions to the second most
prevalent conformation that is primarily defined by interruption
of the intramolecular hydrogen-bond and rotation of the
hexaketide tail away from His268 resulting in poor shape
complementarity with the TE active site and a more linear
conformation of the hexaketide (II′, Figure 4b). These two
unproductive conformations are alternately sampled for the
majority of the simulation (∼470 ns). Afterwards, the
hexaketide chain evolves toward even more extended
conformations (III′, Figure 4b) characterized by a gradual
loss of hydrophobic interactions with the protein, and
formation of unproductive hydrogen bonds between the C-11
alcohol and Glu85 (Figure S13). This conformation impedes
macrolactonization and increases the likelihood competing
hydrolysis of the acyl-enzyme intermediate will occur.
We next compared the frequency of productive conforma-
tions sampled in the MD simulations (Figure 5) by calculating
quantum mechanically (QM) optimized macrolactonization
transition structures (TS) for each hexaketide (vide inf ra). We
used these models to describe the precise angle of nucleophilic
attack (O11−C1−O1) and distance (O11−C1) for macro-
lactonization of each hexaketide. The resulting geometric values
were then compared to those extracted from each frame of the
corresponding MD simulations and the entire trajectories were
plotted according to their deviation from the ideal TS values
(Figure 5). Consistent with our clustering analysis of the
hexaketide conformations, comparison of the geometric
deviations from ideal within each simulation revealed that Pik
TE-4 contained more frames with the hexaketide in a position
favorable to macrolactonization (Figure 5c). In contrast, Pik
TE-5 presented a larger distribution of geometries with very
few catalytically productive structures (Figure 5d). Taken
together, the MD results on the covalent acyl-enzyme
intermediates indicate that hydrophobic interactions accom-
panying a high level of substrate-TE shape complementarity are
critical for maintaining each hexaketide in a catalytically
productive conformation. These contacts are, to a lesser extent,
maintained in simulations containing the C-11-epimerized
hexaketide 5, indicating that the Pik TE active site has sufficient
flexibility to accommodate both epimers. The intrinsic
conformational preferences of each hexaketide further influence
catalysis. The acyl intermediates must reach conformations that
are matched for deprotonation by His268 and subsequent
nucleophilic attack in order to achieve macrolactonization.
When these structural preferences are perturbed, as in the case
with Pik TE-5, the energetic barrier to macrolactonization is
increased above that of competing hydrolysis.
Chemical Lactonizations. As the MD simulations
containing covalently bound hexaketides 4 and 5 revealed
that both substrates are accommodated by the Pik TE active
site, we next investigated if macrolactonization of the C-11-
epimerized 5 suffered in bulk solution outside of enzymatic
constraints. Starting with conditions employed for similar seco-
acids,11,12 we screened contemporary lactonization method-
ologies capable of cyclizing 8 to 6. Optimization of Yamaguchi
conditions originally reported from the total synthesis of
spinosyn analogs,13 enabled direct comparison of lactonization
efficiency of 8 and 7. Employing identical reaction conditions
resulted in 73% and 6% conversions to generate 6 and 9,
respectively (Scheme 1). This result confirmed the intrinsically
poor reactivity of 7 toward macrocyclization compared to 8,
corroborating the MD findings that the lack of macrolactone
formation with the C-11-epimerized hexaketide is not due to
steric clashes within the Pik TE active site.
Pik TES148C Macrolactonization of epi-Hexaketide 5. As
the strict substrate stereoselectivity of Pik TEWT does not arise
from inherent steric clashes within the TE active site, we
considered the excised Pik TE domain to be a prime
engineering target to generate a catalyst capable of cyclizing
5. We envisioned that altering substrate specificity would likely
require a protracted directed evolution campaign and, if
successful, would potentially yield a variant incapable of
cyclizing the starting, native substrate 3. Prior to library
generation, we performed preliminary site directed mutagenesis
on select residues in the active site, including a serine to
cysteine mutation of the serine-histidine-aspartate catalytic
triad.14,15 Remarkably, this variant was able to efficiently cyclize
Figure 5. Procatalytic sampling of Pik TE during MD simulations.
(a,b) Low-energy QM optimized transition states for macrolactoniza-
tion of Pik hexaketides (a) Pik TE-4 and (b) Pik TE-5. Nonpolar
hydrogens have been removed for clarity. (c,d) Deviations of the key
catalytic distances (x axis) and angles (y axis) in the MD simulations of
(c) Pik TE-4 and (d) Pik TE-5 from their respective optimized
transition structure (green square at the origin of coordinates). Each
point represents a single frame from the 550 ns simulation, while the
shaded rectangles represent frames from the MD that are likely in a
catalytically productive state.
Scheme 1. Yamaguchi Macrolactonization of Methyl-
Protected Hexaketidesa
aConversion of 8 to 6 and 7 to 9 was monitored by HPLC, with data
represented as the mean ± standard deviation, where n = 3.
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5 to 9 while also displaying improved native functionality
(Scheme 2).
Kinetic Analysis of Pik TE WT and S148C. In addition to
the gain-of-function macrolactonization of 5, we also examined
the kinetic effect of the S148C mutation on cyclization (Table
1). Steady-state kinetic analysis of Pik TEWT and TES148C was
performed using both methyl-protected Pik hexaketides 4 and
5, as well as the previously reported NBOM-protected10 native
hexaketide 3, following a procedure similar to one used
previously.16 Kinetic analysis revealed that the serine to cysteine
substitution afforded a superior cyclization catalyst for each
substrate tested. Pik TES148C displayed a 4.3- and 12-fold
increase in the kcat/Km for macrolactonization of both the native
(3) and C-3 methoxy hexaketide 4 compared to Pik TEWT,
respectively. In reactions containing methyl-protected epimer-
ized 5, not only did Pik TES148C retain the ability to catalyze
macrolactonization of the linear substrate, but notably the kcat/
Km was 5.5-fold higher than for Pik TEWT-catalyzed hydrolysis.
In addition to increased substrate flexibility of Pik TES148C, the
gain-of-function mutation provided a 2.6-fold rate enhancement
with the native hexaketide 3 over wild type. These kinetic
parameters demonstrate that the S148C mutation of Pik TE
produces a catalyst with both expanded substrate scope and
increased catalytic efficiency.
Full-Module Processing. We next investigated whether
the engineered Pik TES148C was able to improve substrate
flexibility in the context of full-module catalysis. To accomplish
this, we generated PikAIII-TES148C and incubated it with an
analogous series of epimeric Pik pentaketides. LC-HRMS
analysis of reaction products revealed two new peaks in the
chromatograms not observed in PikAIII-TEWT reactions
(Figure S12), with masses and retention times corresponding
to 12-membered ring macrolactones. As no authentic standards
for the putative novel products were available, a 0.2 mmol scale
reaction of 10 with PikAIII-TES148C was performed and the
reaction products were purified and characterized via MS and
NMR. Structural determination of the reaction products
confirmed that PikAIII-TES148C was indeed able to generate
11-epi-10-dml 11 from 10, as well as 3-keto-11-epi-10-dml 12,
due to failed reduction of the β-keto intermediate by the
PikAIII KR domain prior to transfer to the terminal TE domain
(Scheme 3).
Diminished relative KR activity has been previously observed
in vitro by the production of both the predicted reduced and 3-
keto macrolactones from reactions containing Ery5-TE with
DEBS pentaketide.17 Additionally, PikAIII-PikAIV chimeras18
lacking a KR domain yielded exclusively 3-keto-10-dml when
incubated with Pik pentaketide in vivo, indicating that the WT
Pik TE domain is capable of cyclizing the C-3 keto
intermediate. We next investigated if the KR-TE domain
competition observed in PikAIII-TES148C reactions with 10 also
occurred with the native Pik pentaketide. Accordingly, we
performed analytical scale reactions containing PikAIII-TES148C
with its native substrate and analyzed the product distribution
using synthetic standards for each product. HPLC quantifica-
Scheme 2. Evaluation of Pik TES148C with Methyl-Protected
Hexaketides 4 and 5a
aEnzymatic reaction conditions: 1 mM hexaketide, 8 mM 2-
vinylpyridine, purified Pik TES148C (10 μM), 4 h, stationary, RT.
Conversion of 4 to 6 and 5 to 9 was monitored (HPLC), with data
represented as the mean ± standard deviation, where n = 3.
Table 1. Steady-State Kinetic Values for Pik TEWT and TES148C
substrate TE reaction kcat (min
−1) Km (mM) kcat/Km (mM
−1 min−1)
3
WT cyclization 101.7 ± 8.2 4.06 ± 0.68 25.1 ± 0.19
S148C cyclization 261.7 ± 19.6 2.40 ± 0.46 109 ± 0.21
4
WT cyclization 11.61 ± 0.24 4.46 ± 0.18 2.60 ± 0.05
S148C cyclization 44.39 ± 2.01 1.42 ± 0.16 31.3 ± 0.12
5
WT hydrolysis 8.58 ± 0.42 1.04 ± 0.16 8.25 ± 0.16
S148C cyclization 3.37 ± 0.09 0.07 ± 0.01 50 ± 0.4
Scheme 3. Reaction of PikAIII-TES148C with C-9-Epimerized
Pentaketide 10a
aEnzymatic reaction conditions: 1 mM Pik pentaketide, 20 mM (20
equiv) MM-NAC, 8 mM (8 equiv) 2-vinylpyridine, 0.5 mM (50 mol
%) NADP+, 2.5 mM (2.5 equiv) glucose-6-phosphate, glucose-6-
phosphate dehydrogenase (2 units/mL), 3 μM (0.3 mol %) PikAIII-
TES148C, 8 h, stationary, RT.
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tion of the reaction products revealed the conversion of native
pentaketide to 3-keto-10-dml and 10-dml (1) to be 5.5% and
12.5%, respectively (see Supporting Information). Generation
of both the reduced and unreduced macrolactone products
indicates competition for the linear hexaketide intermediate
between the KR and TE domains even in the context of the
native substrate. Isolation of 11 and 12 at 12% yields indicates
that the identified thioesterase bottleneck had been alleviated
by a single amino acid change (S148C) enabling substrate flux
to generate novel epimerized macrolactones.
Quantum Mechanical (QM) Modeling of Pik TE
Macrolactonization. Since MD simulations revealed the Pik
TEWT active site to be competent in binding the unnatural
substrate 5, we hypothesized the catalytic advantages imparted
by the S148C mutation were kinetic in nature as opposed to
structural. To further our understanding of the energetics of
these processes and how Pik TES148C is able to overcome the
barrier to macrolactone formation with 5, we turned to QM
modeling of the catalytic steps comprising macrolactonization
(see Computational Details in the Supporting Information)
after formation of the acyl-enzyme intermediate. To accomplish
this, we generated abbreviated active site models (theozymes19)
for Pik TEWT and Pik TES148C containing the native C-3-
unprotected hexaketide (Pik TEWT-13 and Pik TES148C-13) and
the C-11-epi hexaketide (Pik TEWT-14 and Pik TES148C-14).
Analysis of the resulting free energy landscapes revealed that
macrolactonization of the linear hexaketide intermediates is an
exergonic process in all four systems after product release
(Figure 6). Cyclization of the native hexaketide was more
thermodynamically favorable compared to C-11-epimerized
hexaketide, particularly with the wild-type enzyme. Moreover,
the macrolactonization mechanism with each TE was calculated
to change from a stepwise addition−elimination with existence
of a tetrahedral intermediate in Pik TEWT to a concerted acyl
substitution20 upon the S148C mutation. This change in
mechanism was evidenced by the flat potential energy surface
which precludes the formation of a tetrahedral intermediate.
Figure 7 shows the lowest energy transition structures and
associated activation barriers (ΔG⧧) for the macrolactonization
of the acyl intermediates of both the natural 13 and C-11-
epimerized 14 substrates with the Pik TEWT and TES148C
protein models. The rate-limiting activation barriers for the
TES148C-catalyzed reactions are significantly lower than those
for the TEWT reactions, which correspond to the final Ser148-
acyl cleavage. Thus, Pik TES148C performs the macrolactoniza-
tion of the native and C-11-epimerized hexaketides with ΔG⧧
values of 14.8 and 16.0 kcal mol−1, respectively, while Pik TEWT
displays ΔG⧧ values of 18.2 and 22.4 kcal mol−1 for the same
substrates (Figure 7). These values predict that the rate of
reactions containing the native hexaketide after the formation
of the acyl-enzyme intermediate is faster in Pik TES148C
compared to TEWT.
The calculated increase of 4.2 kcal mol−1 in the activation
barrier of the macrolactonization of Pik TEWT-13 vs Pik TEWT-
14, agrees well with the experimentally observed lack of
epimerized macrolactone formation. This higher macrolactoni-
zation energy barrier in the TEWT system increases the difficulty
in proceeding from the acyl-enzyme intermediate, which is
vulnerable to water hydrolysis.6 While we did not observe
significant water hydrolysis in reactions containing Pik TEWT
and the native substrate, incubation with epimerized methyl-
protected 5 resulted exclusively in hydrolyzed product, the
result of an inability to form the epimerized macrolactone 9. In
contrast, the 6.4 kcal mol−1 decrease in activation barrier for Pik
TES148C-14 macrolactonization is consistent with our exper-
imentally observed product formation.
■ DISCUSSION
TE Substrate Tolerance. In vivo engineering of the DEBS
biosynthetic pathway has shown that DEBS TE possesses some
Figure 6. Reaction coordinate diagram representing the relative free energies for Pik TE-catalyzed macrolactonization of hexaketides 13 and 14.
Calculations were performed at the PCM/M06-2X/6-31+G(d,p) level using reduced models that define the enzymatic active site (theozymes19).
Relative free energies are in kcal mol−1. Only the lowest energy conformers are represented; see Supporting Information for details and all the
calculated structures. *This intermediate is higher in energy than its preceding TS due to conformational differences between both stationary points.
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tolerance to modifications in both the length and the
functionality of the linear polyketide substrate. Modifications
in the DEBS pathway have yielded a large number of 6-dEB
analogs from differential extender unit incorporation and
reductive processing21−28 as well as macrolactones ranging in
size from 6- to 16-membered rings.29−32 However, the titers of
these unnatural products are greatly diminished compared to
wild type production levels,6 and the inherent complexity of in
vivo biosynthesis has prevented identification of pathway
bottlenecks, such as TE domains.
Initial in vitro biochemical characterization of the DEBS
TE33,34 provided further evidence for the relatively high
substrate tolerance of PKS TEs for acylation and hydrolysis,
as terminally (omega) hydroxylated fatty acids and substrates
resembling simplified DEBS heptaketides were all hydrolyzed
by DEBS TE. However, the ability of PKS TEs to cyclize
substrates other than their native linear intermediates has
proved to be much more limited. In fact, TE mediated
macrolactonization has only been observed in a select few
studies.10,16,35−42
In addition to their native substrates, Pik TE has been shown
to catalyze macrolactonization of C-3 methyl 4 and NBOM-
protected derivatives,10 though not C-7 reduced analogs.16,36
DEBS TE has been shown to catalyze macrolactonization of
unnatural mimics of the DEBS heptaketide.39,42 However, there
are no reports of either the Pik or DEBS TEs catalyzing
macrolactonization of a substrate containing a nucleophilic
hydroxyl group with an unnatural, epimerized (S)-config-
uration. When probed for the ability to form an epimeric
heptaketide mimic of 6-dEB, the DEBS TE displayed a high
level of stereoselectivity for the natural (R)-configuration, and
exclusively hydrolyzed the unnatural (S)-stereoisomer,42 adding
to the observations in this study for strict stereoselectivity in
TE-catalyzed macrolactonization.
PKS Catalysis with Engineered TE Domains. In an
preceding article, we describe the identification of the TE
domain as a catalytic bottleneck in the processing of unnatural
substrates. Accordingly, we have engineered the TE domain for
increased substrate flexibility and introduced it into PikAIII-TE
to yield the engineered variant PikAIII-TES148C.
Direct comparison of PikAIII-TEWT to PikAIII-TES148C with
a panel of stereoisomer Pik pentaketides demonstrated the
success of this approach as a 0.2 mmol scale reaction with 10
resulted in the production of two new macrolactone products,
11-epi-10-dml 11 and 3-keto-11-epi-10-dml 12. The 1:1
isolation of 11 and 12 from reactions of 10 with PikAIII-
TES148C indicates that the TE was indeed responsible for the
failed catalysis using PikAIII-TEWT, as the KR domain retained
a sufficient level of activity toward the unnatural intermediate.
This demonstration of TE engineering offers a potential means
for increasing the substrate flexibility of biosynthetic pathways
for the production of natural product analogs.
In a previous report we assayed a series of different thio- and
oxoester-protected hexaketides against the terminal Pik module
(PikAIV) as well as the excised TE domain.10 We found that
thio- or oxoester choice determined the catalytic route of the
hexaketide in the presence of PikAIV in vitro, with thiophenol
and N-acetylcysteamine thioesters having a 10:1 preference for
either full-module processing or direct cyclization, respectively.
Moreover, previous studies have demonstrated that TE
Figure 7. Lowest energy rate-limiting transition structures calculated with PCM/M06-2X/6-31+G(d,p) for the abbreviated active site models
(theozymes19) of the Pik TEWT (left) and Pik TES148C (right) catalyzed macrolactonization of native hexaketide 13 (top, in blue) and C-11-epi
hexaketide 14 (bottom, in red). Activation free energies (ΔG⧧) calculated from the corresponding Pik TE hexaketides are given in kcal mol−1 and
distances in angstroms. Relevant breaking/forming C−O and C−S bonds are shown in boldface. Nonpolar hydrogens have been removed for clarity.
See Supporting Information for all calculated structures along the reaction pathway.
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domains can function as hydrolases with a large degree of
substrate flexibility.16,17 Thus, we reasoned that the low yields
from the PikAIII-TES148C reactions with 10 are likely due to
direct loading of the TES148C domain and subsequent
hydrolysis. Indeed, control reactions (see Supporting Informa-
tion) confirmed (i) the S148C mutation overrides the KS
preference previously enjoyed by thiophenol thioesters and (ii)
enzymatic reactions performed without extender unit or
reductive cofactors showed a much higher hydrolysis of Pik
pentaketide with PikAIII-TES148C relative to wild type.
Recently, Schaffer et al. reported a TE domain with a native
cysteine nucleophile critical to the cyclization of a strained β-
lactone ring in the obafluorin (Obi) nonribosomal peptide
pathway.43 Of note, an analogous cysteine to serine mutation in
the Obi TE resulted solely in the hydrolysis product, further
implicating the catalytic advantage of a cysteine TE in the
cyclization of strained ring systems. Examples of modular type I
polyketide TE domains containing cysteine active site
nucleophiles are notably rare.6 Further studies will focus on
delineating the biosynthetic parameters that select for cysteine
or serine active site residues.
Computational Investigation of the TE Domain
Catalysis. Our investigation revealed mutual recognition, TE-
substrate shape complementarity, and intrinsic substrate
structural preferences to be critical for the hexaketide to
reach a conformation productive toward macrolactonization.
MD simulations revealed hydrophobic interactions between the
substrate and TE residues lining the active site as being vital for
guiding the hexaketide to a catalytically competent pro-cyclic
conformation. These findings are consistent with mutational
analysis of DEBS TE where exchange of potential hydrogen-
bonding residues did not substantively affect the specificity
constant for hydrolysis of four unnatural thioester substrates. In
this case, Wang and Boddy suggested that hydrophobic
interactions between the active site and substrate are the
main driving force of substrate specificity.37 Additionally, our
results are in agreement with the available crystal structures of
Pik TE bound with phosphonate substrate mimics, which
displayed a lack of specific TE-substrate polar contacts.7,8
Recently, Chen et al.44 reported theoretical investigations of
the thioesterase domain from the erythromycin biosynthetic
pathway (DEBS TE) to describe the mechanistic parameters
that determine the catalytic partitioning of substrates to either
macrocyclic or linear hydrolysis products. MD simulations
coupled with QM calculations were performed on systems of
DEBS TE modeled with the native DEBS heptaketide and Pik
hexaketide, which both lead to macrolactonization, as well as
two diastereomers of a reduced C-7 hydroxyl analog of Pik
hexaketide that result exclusively in substrate hydrolysis.
Analysis of the resulting MD simulations provided findings
consistent with those in this report, particularly highlighting the
importance of the formation of a substrate pre-reaction state
through induced-fit mutual recognition between the enzyme
and the substrate for macrolactonization to occur. Consistent
with the present study, the authors found a hydrogen bond
between the lactonizing hydroxyl group of the substrate and the
catalytic histidine as well as hydrophobic interactions to be
critical for formation of a catalytically competent pre-reaction
state.
To understand the energetic consequences of the S148C
mutation during the macrolactonization process, we performed
DFT analysis of Pik TEWT and TES148C modeled as acyl-enzyme
intermediates with the native and C-11-epimerized hexaketides.
The results of our QM calculations revealed a significant kinetic
advantage in the reactions catalyzed by Pik TES148C. The S148C
mutation provides a mechanistic change during the macro-
lactonization step from a two-step transesterification in the
TEWT reaction (i.e., addition−elimination) to a lower energy
single concerted step in the TES148C pathway.
Overall, our combined computational method for investigat-
ing Pik TE catalysis using MD simulations in concert with QM
calculations provides a plausible explanation for improved
substrate flexibility and catalytic efficiency of Pik TES148C.
According to the results from our MD simulations,
epimerization of the hexaketide C-11 stereocenter generates a
substrate with a reduced propensity for acquiring a catalytically
competent conformation within the TE active site. However,
the ability of the hexaketides to reach a conformation viable for
catalysis is not the only factor affecting macrocylicization,
especially if this step is not rate-limiting.44 Hence, even if a
substrate has a poor propensity to arrange in a productive
conformation and/or lactonization is structurally hindered (as
with the C-11-epimerized hexaketide) a significant acceleration
through a key single mutation can overcome these structural
limitations, boosting reactivity even with unnatural substrates.
■ CONCLUSION
Based on the TE catalytic stringency observed in the processing
of unnatural substrates,9 we focused the current study on
investigating full-length substrate analogs as probes for the Pik
TE domain and describe the identification of a single active site
mutation that generates a more effective macrolactonization
catalyst. Remarkably, this single S148C mutation provided a Pik
TE variant with increases in both substrate scope and catalytic
efficiency. Notably, Pik TES148C was able to catalyze the
cyclization of a hexaketide with an epimerized nucleophilic
hydroxyl to generate a novel epimerized macrolactone, while
TEWT catalyzed complete hydrolysis of the same substrate due
to inefficient macrocyclization. Furthermore, application of the
engineered TE through reactions containing PikAIII-TES148C
allowed for the full-module processing of a C-9-epimerized Pik
pentaketide 10 to the corresponding epimeric macrolactones
11 and 12. Computational investigation of both variants
revealed that a single mutation greatly lowers the activation
barriers to macrolactonization; as a consequence, the catalytic
process occurs faster and the substrate specificity previously
dictated by shape complementarity is kinetically overcome, in
line with the observed increase in kcat.
Notably, in the context of our system, the KR domain of
PikAIII-TES148C displayed diminished relative activity for both
the native Pik pentaketide as well as 10 with an epimerized
distal hydroxyl stereocenter. The product distribution indicates
competition between the KR mediated β-keto reduction and
TE cyclization of the linear hexaketide intermediate. This
competition is remarkable since the KR domain is fully
competent toward processing the native substrate and no
unreduced products are observed in reactions containing
PikAIII-TEWT, suggesting that the engineered TE domain is able
to outcompete the native catalytic sequence.45,46 While this domain
competition for the hexaketide intermediate diminished the
product yields for 11-epi-10-dml 11, it provides insight into the
effects of engineered domains on the sequence of catalytic
events in PKS catalysis.
While additional biochemical studies of excised domains and
full-modules with full-length analogs of native substrates are
necessary to support and expand our understanding of PKS
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function, it is becoming apparent that efficient production of
specific, designer macrolide analogs will require significant
pathway engineering. However, production of a desired natural
product analog should be obtainable through the following
workflow: (i) a targeted domain is engineered to perform an
unnatural function; (ii) downstream modules are biochemically
characterized in vitro with the resulting unnatural polyketide in
order to identify bottlenecks; and (iii) catalytically inefficient
domain(s) are engineered with the goal of restoring effective
processing to generate unnatural products. Indeed, as noted in
a recent review by Weissman,47 it is perhaps more realistic to
envision the future application of PKS engineering as a
synthetic biology tool for producing specific, high-value natural
product derivatives through targeted reprogramming of
modular type I polyketide pathways rather than generation of
natural product libraries.
The results described herein lay the groundwork for future
engineering of PKS TE domains in order to generate more
flexible catalysts for the production of novel natural product
analogs.
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